Reports Q1 product revenue $2.21M vs $2.35M last year. Mytesi prescription volume increased by approximately 1.8% in Q1 2025 over Q1 2024 and decreased by approximately 13.5% in Q1 2025 over Q4 2024.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAGX:
- Jaguar Health Highlights Promising Crofelemer Study Results
- Jaguar Health provides overview of 2025 crofelemer-related catalysts
- Jaguar Health’s Napo reports initial PoC results from trial of crofelemer
- Jaguar Health Announces Promising Crofelemer Trial Results
- Biotech Alert: Searches spiking for these stocks today